Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Shares Outstanding (Weighted Average) (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $93.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 3.14% to $93.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $93.3 million, a 3.14% increase, with the full-year FY2024 number at $90.3 million, up 22.37% from a year prior.
  • Shares Outstanding (Weighted Average) was $93.3 million for Q3 2025 at Caribou Biosciences, roughly flat from $93.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $93.3 million in Q3 2025 to a low of $9.5 million in Q1 2021.
  • A 5-year average of $64.3 million and a median of $61.3 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 537.37% in 2022, then rose 0.9% in 2023.
  • Caribou Biosciences' Shares Outstanding (Weighted Average) stood at $31.7 million in 2021, then soared by 92.02% to $60.8 million in 2022, then increased by 21.39% to $73.8 million in 2023, then increased by 22.37% to $90.3 million in 2024, then rose by 3.29% to $93.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Shares Outstanding (Weighted Average) are $93.3 million (Q3 2025), $93.0 million (Q2 2025), and $92.7 million (Q1 2025).